Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 8ibrutinib 5fludarabine phosphate 5fludarabine 5pirtobrutinib 4Mesna 4obinutuzumab 3acalabrutinib 3Mycophenolic Acid 3Melphalan 3venetoclax 2Whole-Body Irradiation 2Tacrolimus 2Rituximab 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Busulfan 2Bone Marrow Transplantation 2ARQ531 2ricolinostat 1idelalisib 1idecabtagene vicleucel 1Vincristine 1Stem Cell Transplantation 1Rabeprazole 1Prednisone 1Leukapheresis 1Itraconazole 1Filgrastim 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, B-Cell × ricolinostat × 1 year × Clear all
NCT02787369 2026-05-19

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
3 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡